strong>Abbvie Inc., of North Chicago, said it entered an exclusive worldwide license agreement with C2N Diagnostics, of St. Louis, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease and other neurological disorders.